First National Advisers LLC Takes $821,000 Position in Revvity, Inc. (NYSE:RVTY)

First National Advisers LLC purchased a new position in shares of Revvity, Inc. (NYSE:RVTY - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 7,515 shares of the company's stock, valued at approximately $821,000.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. acquired a new position in shares of Revvity in the 3rd quarter valued at $1,579,487,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Revvity during the fourth quarter worth about $188,368,000. Dimensional Fund Advisors LP purchased a new stake in shares of Revvity in the 4th quarter valued at about $112,037,000. Ceredex Value Advisors LLC acquired a new stake in shares of Revvity in the 4th quarter valued at about $108,353,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Revvity in the 4th quarter valued at about $83,647,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Price Performance

RVTY stock traded up $1.77 on Friday, reaching $110.23. 1,087,199 shares of the company's stock were exchanged, compared to its average volume of 775,315. Revvity, Inc. has a twelve month low of $79.50 and a twelve month high of $131.96. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40. The stock has a fifty day moving average of $104.19 and a 200-day moving average of $101.99. The firm has a market cap of $13.60 billion, a PE ratio of 91.10, a P/E/G ratio of 2.87 and a beta of 1.09.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The business had revenue of $649.90 million during the quarter, compared to the consensus estimate of $646.83 million. During the same quarter last year, the firm posted $1.01 EPS. The business's revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts predict that Revvity, Inc. will post 4.66 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend is Friday, July 19th. Revvity's dividend payout ratio is currently 23.14%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RVTY. KeyCorp increased their price objective on Revvity from $110.00 to $126.00 and gave the company an "overweight" rating in a report on Friday, February 2nd. TD Cowen lifted their price objective on shares of Revvity from $123.00 to $130.00 and gave the company a "buy" rating in a research note on Tuesday, April 30th. Stifel Nicolaus upped their target price on shares of Revvity from $95.00 to $110.00 and gave the company a "hold" rating in a report on Friday, February 2nd. Robert W. Baird raised their price target on Revvity from $126.00 to $127.00 and gave the stock an "outperform" rating in a report on Tuesday, April 30th. Finally, Barclays upped their price objective on Revvity from $92.00 to $105.00 and gave the company an "equal weight" rating in a research note on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $118.17.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.